Department of the Army, DoD.
In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent Application No. 09/952,078 entitled “Method for Detecting Clostridium Botulinum Neurotoxin Serotypes A, B, E and F in a Sample” filed September 14, 2001. Foreign rights are also available (PCT/US01/28641). The United States Government as represented by the Secretary of the Army has rights in this invention.
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012.Start Further Info
FOR FURTHER INFORMATION CONTACT:
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.Start Printed Page 11107End Further Info End Preamble Start Supplemental Information
Sensitive and specific enzyme-linked immunosorbent assays which detect Clostridium botulinum neurotoxins serotypes A, B, E, and F in a sample are described. The assay is based upon affinity-purified antibodies directed against the C-fragments of each toxin. These assays demonstrate sensitivity close to that on the mouse bioassay without the use of animals and in a much simpler format than other assays of similar sensitivity.Start Signature
Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-5899 Filed 3-11-02; 8:45 am]
BILLING CODE 3710-08-M